These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 26988747)

  • 21. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease.
    Parkinson Study Group
    Arch Neurol; 2004 Apr; 61(4):561-6. PubMed ID: 15096406
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term outcome of early versus delayed rasagiline treatment in early Parkinson's disease.
    Hauser RA; Lew MF; Hurtig HI; Ondo WG; Wojcieszek J; Fitzer-Attas CJ;
    Mov Disord; 2009 Mar; 24(4):564-73. PubMed ID: 19086083
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rasagiline-associated motor improvement in PD occurs without worsening of cognitive and behavioral symptoms.
    Elmer L; Schwid S; Eberly S; Goetz C; Fahn S; Kieburtz K; Oakes D; Blindauer K; Salzman P; Oren S; Prisco UL; Stern M; Shoulson I; ;
    J Neurol Sci; 2006 Oct; 248(1-2):78-83. PubMed ID: 16828804
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Rasagiline in daily clinical use. Results of a treatment study of Parkinson patients with a combination treatment].
    Jost WH; Klasser M; Reichmann H
    Fortschr Neurol Psychiatr; 2008 Oct; 76(10):594-9. PubMed ID: 18833504
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A randomized clinical trial to evaluate the effects of rasagiline on depressive symptoms in non-demented Parkinson's disease patients.
    Barone P; Santangelo G; Morgante L; Onofrj M; Meco G; Abbruzzese G; Bonuccelli U; Cossu G; Pezzoli G; Stanzione P; Lopiano L; Antonini A; Tinazzi M
    Eur J Neurol; 2015 Aug; 22(8):1184-91. PubMed ID: 25962410
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Double-blind, randomized, controlled trial of rasagiline as monotherapy in early Parkinson's disease patients.
    Stern MB; Marek KL; Friedman J; Hauser RA; LeWitt PA; Tarsy D; Olanow CW
    Mov Disord; 2004 Aug; 19(8):916-23. PubMed ID: 15300656
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Randomized, controlled trial of rasagiline as an add-on to dopamine agonists in Parkinson's disease.
    Hauser RA; Silver D; Choudhry A; Eyal E; Isaacson S;
    Mov Disord; 2014 Jul; 29(8):1028-34. PubMed ID: 24919813
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rasagiline in Parkinson's disease: a review based on meta-analysis of clinical data.
    Mínguez-Mínguez S; Solís-García Del Pozo J; Jordán J
    Pharmacol Res; 2013 Aug; 74():78-86. PubMed ID: 23735235
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rasagiline adjunct therapy in patients with Parkinson's disease: post hoc analyses of the PRESTO and LARGO trials.
    Elmer LW
    Parkinsonism Relat Disord; 2013 Nov; 19(11):930-6. PubMed ID: 23849501
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rasagiline treatment effects on parkinsonian tremor.
    Lew MF
    Int J Neurosci; 2013 Dec; 123(12):859-65. PubMed ID: 23767986
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term, open-label, phase 3 study of rasagiline in Japanese patients with early Parkinson's disease.
    Hattori N; Takeda A; Takeda S; Nishimura A; Kitagawa T; Mochizuki H; Nagai M; Takahashi R
    J Neural Transm (Vienna); 2019 Mar; 126(3):299-308. PubMed ID: 30689042
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Benefits of treatment with rasagiline for fatigue symptoms in patients with early Parkinson's disease.
    Stocchi F;
    Eur J Neurol; 2014 Feb; 21(2):357-60. PubMed ID: 23790011
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson's disease.
    Guay DR
    Am J Geriatr Pharmacother; 2006 Dec; 4(4):330-46. PubMed ID: 17296539
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of rasagiline monotherapy for early Parkinson disease: A systematic review and meta-analysis of randomized controlled trials.
    Chang HY; Li YY; Hong CT; Kuan YC
    J Psychopharmacol; 2022 Jun; 36(6):704-714. PubMed ID: 35546511
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A randomized trial of a low-dose Rasagiline and Pramipexole combination (P2B001) in early Parkinson's disease.
    Olanow CW; Kieburtz K; Leinonen M; Elmer L; Giladi N; Hauser RA; Klepiskaya OS; Kreitzman DL; Lew MF; Russell DS; Kadosh S; Litman P; Friedman H; Linvah N; The P B Study Group F
    Mov Disord; 2017 May; 32(5):783-789. PubMed ID: 28370340
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Patterns and predictors of freezing of gait improvement following rasagiline therapy: A pilot study.
    Rahimi F; Roberts AC; Jog M
    Clin Neurol Neurosurg; 2016 Nov; 150():117-124. PubMed ID: 27618783
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Explaining ADAGIO: a critical review of the biological basis for the clinical effects of rasagiline.
    Jenner P; Langston JW
    Mov Disord; 2011 Nov; 26(13):2316-23. PubMed ID: 21953831
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety and efficacy of rasagiline in addition to levodopa for the treatment of idiopathic Parkinson's disease: a meta-analysis of randomised controlled trials.
    Cai JP; Chen WJ; Lin Y; Cai B; Wang N
    Eur Neurol; 2015; 73(1-2):5-12. PubMed ID: 25358603
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study.
    Parkinson Study Group
    Arch Neurol; 2002 Dec; 59(12):1937-43. PubMed ID: 12470183
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Pharmacological properties and clinical efficacy of rasagiline mesylate (Azilect
    Nagai M; Hattori N
    Nihon Yakurigaku Zasshi; 2020; 155(3):187-194. PubMed ID: 32378642
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.